Whales with a lot of money to spend have taken a noticeably bullish stance on Exact Sciences.
Looking at options history for Exact Sciences EXAS we detected 29 trades.
If we consider the specifics of each trade, it is accurate to state that 79% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $177,320 and 23, calls, for a total amount of $2,283,735.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $65.0 to $80.0 for Exact Sciences over the recent three months.
Insights into Volume & Open Interest
In today's trading context, the average open interest for options of Exact Sciences stands at 2967.42, with a total volume reaching 17,971.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Exact Sciences, situated within the strike price corridor from $65.0 to $80.0, throughout the last 30 days.
Exact Sciences Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXAS | CALL | SWEEP | BEARISH | 04/19/24 | $13.4 | $11.3 | $11.3 | $65.00 | $380.8K | 20.1K | 29 |
| EXAS | CALL | SWEEP | BULLISH | 04/19/24 | $7.5 | $7.4 | $7.5 | $70.00 | $312.1K | 6.1K | 51 |
| EXAS | CALL | SWEEP | BEARISH | 04/19/24 | $11.6 | $11.5 | $11.5 | $65.00 | $309.3K | 20.1K | 1.1K |
| EXAS | CALL | TRADE | BULLISH | 04/19/24 | $3.8 | $3.6 | $3.8 | $75.00 | $158.0K | 4.6K | 544 |
| EXAS | CALL | SWEEP | BULLISH | 04/19/24 | $4.0 | $3.9 | $4.0 | $75.00 | $142.0K | 4.6K | 955 |
About Exact Sciences
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
In light of the recent options history for Exact Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Exact Sciences
- With a volume of 11,346,352, the price of EXAS is up 5.65% at $74.39.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 35 days.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Exact Sciences options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
